May 23 2019
A team of researchers at Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, led by Professor Riichiro Abe and Assistant Professor Natsumi Hama identified, in collaboration with researchers at Department of Dermatology of Hokkaido University and other institutions, galectin-7 as a new diagnostic marker of Stevens-Johnson syndrome and toxic epidermal necrolysis, both of which are severe drug eruptions. This is expected to help make an early diagnosis of these severe skin reactions possible, potentially promoting the understanding of the pathogenesis of severe drug eruptions that have remained unknown to date.
Title: Galectin-7 as a potential biomarker of Stevens–Johnson syndrome/ toxic epidermal necrolysis: Identification by targeted proteomics using causative drug-exposed peripheral blood cells
Journal: The Journal of Allergy and Clinical Immunology: In Practice
Authors: Natsumi Hama, Keiko Nishimura, Akito Hasegawa, Akihiko Yuki, Hideaki Kume, Jun Adachi, Manao Kinoshita, Youichi Ogawa, Saeko Nakajima, Takashi Nomura, Hideaki Watanabe, Yoshiko Mizukawa, Takeshi Tomonaga, Hiroshi Shimizu, Riichiro Abe
Elevated cdc42 activity is a key initiation event leading to proteinuria. -Regulation of cdc42 activity could be a promising therapy for nephrotic syndrome.-
Temozolomide and radiation treatment lead to dramatic tumor shrinkage and improvement of hearing in an adult brainstem glioma patient with a rare IDH2 mutation
Fertilizable rat sperm produced in a mouse body by blastocyst complementation